Move over Aricept.
Pfizer will pay Medivation as much as $725 million for rights to a promising experimental drug for Alzheimer's disease, as the world's largest drug maker seeks to boost its pipeline.
Pfizer will pay an initial $225 million for rights to the drug, Dimebon, which is also being developed for Huntington's disease, the companies said on Wednesday.
More
No comments:
Post a Comment